Noveris Health Sciences Inc.

As of June 30, 2026, Noveris Health Sciences Inc. carries a market capitalization of 73.19M, placing it among publicly traded companies globally. Its enterprise value stands at 72.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Noveris Health Sciences Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Noveris Health Sciences Inc. has 58.55M shares outstanding.

As of June 30, 2026, Noveris Health Sciences Inc. trades at a trailing price-to-earnings ratio of 14.66.

As of June 30, 2026, Noveris Health Sciences Inc. trades at an EV/EBITDA multiple of 26.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. Its EV/EBIT multiple of 26.02 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 72.75M versus a market cap of 73.19M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Noveris Health Sciences Inc. maintains a current ratio of 0.31, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -16.66, indicating conservative leverage, while an interest coverage ratio of 57.44 demonstrates strong ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) stands at 331.69, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is negative at -33.26, pointing to unprofitable operations over the period. The company generates approximately - - in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, Noveris Health Sciences Inc. generated - - in revenue and converted that into 1.64M in net income, yielding earnings per share of 0.09. EBITDA reached 2.80M, while operating income came in at -946,283.00.

As of June 30, 2026, Noveris Health Sciences Inc. holds 808,965.00 in cash and equivalents against 371,627.00 in total debt, resulting in a net debt position of -437,338.00. Total book value stands at -2.23M, with working capital of -2.23M providing operational flexibility.

Noveris Health Sciences Inc. produced -1.43M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

Noveris Health Sciences Inc.'s most recent stock split took place on October 21, 2025 with a 50:1 split ratio.

As of June 30, 2026, Noveris Health Sciences Inc. has an Altman Z-Score of -213.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.